Moderna Inc. (NASDAQ:MRNA) is set to clash with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a pivotal London patent trial concerning the development of COVID-19 vaccines.  The High Court is slated to address a legal complaint brought by Moderna. It alleges patent infringement by its competitors in utilizing the mRNA platform crucial to vaccine development, a claim Pfizer and BioNTech have refuted by asserting patent invalidity. Related: Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge. This legal showdown is part of a global series of intellectual property disputes revolving around mRNA technology.  This technology has ...